ArticleAntioxidants & redox signaling2019
rA1M-035, a Physicochemically Improved Human Recombinant α
Article in Antioxidants & redox signaling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Potential biological therapies for severe preeclampsia: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2019Pooled it
- Assessment of potential nephrotoxicity biomarkers after [Scientific reports · 2026Article
- Early apoptotic response in kidney after 177Lu-octreotate administration with or without potential radioprotector α1-microglobulin.Radiation protection dosimetry · 2025Article
- Effects of Recombinant αInternational journal of molecular sciences · 2024Article
- Recombinant αBiomolecules · 2023Article
- Targeting elevated heme levels to treat a mouse model for Diamond-Blackfan Anemia.Experimental hematology · 2022Article
- Kidney Protection with the Radical Scavenger αAntioxidants (Basel, Switzerland) · 2021Review
- Ferryl Hemoglobin and Heme Induce AInternational journal of molecular sciences · 2021Article
- Binding of the human antioxidation protein αRedox biology · 2021Article
- Article
- Structure, Functions, and Physiological Roles of the Lipocalin αFrontiers in physiology · 2021Review
- The Value of Lactate Dehydrogenase in Predicting Rhabdomyolysis-Induced Acute Renal Failure; a Narrative Review.Archives of academic emergency medicine · 2021Review
- The Role of αInternational journal of molecular sciences · 2020Review
- αInternational journal of molecular sciences · 2020Article
- Expression, Purification and Initial Characterization of Functional αFrontiers in plant science · 2020Article
- The heme and radical scavenger αJournal of neuroinflammation · 2019Article
- Protection of Kidney Function with Human Antioxidation Protein αAntioxidants & redox signaling · 2019Review
Corrections and comments
- Erratum issuedCorrection to:2020
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHuman α
resultsA novel recombinant A1M-variant (rA1M-035) with three amino acid substitutions was constructed, successfully expressed, and purified. rA1M-035 had improved solubility and stability compared with rA1M-wt, and showed intact in vitro heme-binding, reductase, antioxidation, and cell protective activities. Both rA1M-035 and rA1M-wt showed, for the first time, potential in vivo protective effects on kidneys using a mouse rhabdomyolysis glycerol injection model of AKI. INNOVATION: A novel recombinant A1M-variant, rA1M-035, was engineered. This protein showed improved solubility and stability compared with rA1M-wt, full in vitro functional activity, and potential protection against AKI in an in vivo rhabdomyolysis mouse model.
conclusionThe new rA1M-035 is a better drug candidate than rA1M-wt for treatment of AKI and preeclampsia in human patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.